P-19 Subgroup Analysis of the Number of Prior Lines of Systemic Therapy and Clinical Outcomes Associated with Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)
P. Merle,J. Edeline,W. Fang,E. Assenat,H. Pan,L. Rimassa,Z. Li,J. Blanc,C. Yen,P. Ross,S. Hu,T. Zhang,A. Tran,G. Shao,M. Bouattour,Y. Chen,J. Wu,B. Li,S. Chica-Duque,Z. Ren
DOI: https://doi.org/10.1016/j.annonc.2022.04.110
IF: 51.769
2022-01-01
Annals of Oncology
Abstract:Tislelizumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, showed clinical activity and was well tolerated in patients with previously treated advanced HCC in the phase 2 RATIONALE-208 study (NCT03419897). This analysis examined the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab. Patients who received ≥ 1 prior line of systemic therapy for advanced HCC, excluding immune checkpoint inhibitors, received tislelizumab 200 mg IV every 3 weeks. The primary endpoint was objective response rate by independent review committee (IRC) (ORR IRC ) per RECIST version 1.1. Secondary endpoints included investigator-assessed (INV) ORR INV , duration of response by IRC (DoR IRC ), DoR by INV (DoR INV ), overall survival (OS), progression-free survival by IRC (PFS IRC ), and safety. As of June 2021, 249 patients were enrolled; 138 had received 1 prior line of therapy and 111 patients had received ≥ 2 prior lines of therapy. Median (m) follow-up duration was 13.3 months and 11.9 months, respectively. Response rate assessed by IRC (1 prior line, ORR IRC =13.0% [95% CI: 7.9, 19.8]; ≥ 2 prior lines, ORR IRC =12.6% [95% CI: 7.1, 20.3]) and by INV (1 prior line, ORR INV =15.2% [95% CI: 9.7, 22.3]; ≥ 2 prior lines, ORR INV =13.5% [95% CI: 7.8, 21.3]) was generally consistent between subgroups. Number of prior lines of therapy did not impact OS (1 prior line, mOS=13.8 months [95% CI: 10.5, 19.1]; ≥ 2 prior lines, mOS=12.4 months [95% CI: 9.9, 15.2]) or PFS (1 prior line, mPFS IRC =2.6 months [95% CI: 1.4, 2.8]; ≥ 2 prior line, mPFS IRC =2.7 months [95% CI: 1.4, 2.8]). mDOR IRC was not reached in either subgroup. mDoR INV was not reached in the 1 prior line subgroup and was 14.6 months [95% CI: 7.6, 27.3] in the ≥ 2 prior lines subgroup. Treatment-emergent adverse events (TEAEs) were consistent between the 1 prior line and ≥ 2 prior lines subgroups; 94.2% vs 95.5% experienced any TEAE, 50.0% vs 48.6% experienced ≥ Grade 3 TEAEs, 38.4% vs 36.0% experienced serious TEAEs, 13.0% vs 9.0% experienced TEAEs that led to treatment discontinuation, 32.6% vs 30.6% experienced TEAEs that led to dose delay, and 11.6% vs 9.0% experienced TEAEs that led to death in the 1 prior line and ≥ 2 prior lines subgroups, respectively. Similarly, treatment-related adverse events (TRAEs) were consistent between the 1 prior line and ≥ 2 prior lines subgroups; 65.9% vs 60.4% experienced any TRAE, 17.4% vs 12.6% experienced ≥ Grade 3 TRAEs, 9.4% vs 4.5% serious TRAEs, 7.2% vs 2.7% experienced TRAEs that led to treatment discontinuation, 19.6% vs 17.1% experienced TRAEs that led to dose delay, and 0% vs 0% experienced TRAEs that led to death in the 1 prior line and ≥ 2 prior lines subgroups, respectively. Effective second- and third-line treatment options are limited for patients with advanced HCC. This analysis indicates Tislelizumab is clinically active and well tolerated in patients with advanced HCC, regardless of the number (1 or ≥ 2) of prior lines of systemic therapy. Tislelizumab is being investigated further in a phase 3 study (NCT03412773).